Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Drug Monitoring. Found 6 abstracts

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat Rev. 2011 Jun;37(4):291-9.   PMCID: not NIH funded
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Held-Warmkessel J. Methotrexate. Clinical journal of oncology nursing. 2000 Jul;4(4):187-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Drug Monitoring

Drug Monitoring drug therapy Antineoplastic Agents Female methods Male therapeutic use antagonists & inhibitors metabolism Treatment Outcome Adult pharmacology Middle Aged blood Aged adverse effects pharmacokinetics Drug Administration Schedule Antineoplastic Antimetabolites Human Pyrimidines Drug Interactions administration & dosage Protein-Tyrosine Kinases Oncologic Nursing nursing Angiopoietin-2 Pyrroles Time Factors chemically induced Cyclopentanes Angiogenesis Inhibitors Vascular Endothelial Growth Factor Receptor-3 Multiple Myeloma Tetrazolium Salts genetics etiology Patient Education as Topic Squamous Cell Carcinoma Maximum Tolerated Dose Neoplasm Antigens Drug Eruptions Single Nucleotide Polymorphism drug effects Vascular Endothelial Growth Factor A Ubiquitins Molecular Targeted Therapy Neoplasm Metastasis Neoplasms Head and Neck Neoplasms Monoclonal Antibodies Renal Cell Carcinoma Nurse's Role Cell Survival Kidney Neoplasms Gastrointestinal Stromal Tumors alpha Subunit Hypoxia-Inducible Factor 1 Prognosis Methotrexate Fluorouracil Neoplasm Drug Resistance Patient Compliance Patient Education Carbonic Anhydrases Premedication Thiazoles Retreatment Von Hippel-Lindau Tumor Suppressor Protein Diarrhea Patient Selection Hypertension Matrix Metalloproteinase 2 Drug Delivery Systems Cisplatin 80 and over Aged Disease-Free Survival secondary Local Neoplasm Recurrence pathology Survival Rate mortality Bone Marrow Diseases Antitumor Drug Screening Assays Piperazines Paronychia Lymphoma Tumor Biomarkers Stomatitis Indoles Metabolic Clearance Rate Interstitial Lung Diseases Biomarkers diagnosis Hemorrhage
Last updated on Wednesday, February 05, 2020